- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03746860
N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France (CARIOCA)
Non-interventional Study on the Safety and Use of Allergy Immunotherapy ACARIZAX® 12 SQ-HDM in Real-life Clinical Practice in Adult Patients With House Dust Mite Allergy in France
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Condition:
- persistent moderate to severe HDM allergic rhinitis despite use of symptom-relieving medication
- HDM allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe HDM allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34090
- Hôpital Arnaud de Villeneuve
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Adults suffering of HDM allergic rhinitis or HDM allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe HDM allergic rhinitis.
Patients are only included in the study after the decision for treatment with ACARIZAX® has already been made, and only with the objective of documenting data that reflects the treatment and its safety under 'real life' conditions. Accordingly, only examinations and inquiries conforming to routine practice are conducted and documented.
Description
Inclusion Criteria:
- At the discretion of the investigator, patient who will be prescribed ACARIZAX® in line with the approved Summary of Product Characteristics (SmPC) and who have been informed, after explicit written explanation and willing to participate in the study by signed consent
Exclusion Criteria:
- Patient who did not have 12 months prior inclusion or have an on-going, House Dust Mite (HDM) Allergy Immunotherapy (AIT).
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety analysis: Number of patients with at least one Adverse Event
Time Frame: 1 year
|
Number of patients with at least one Adverse Events related to ACARIZAX®.
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Pascal DEMOLY, Pr, Hôpital Arnaud de Villeneuve - 34090 Montpellier - FRANCE
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Otorhinolaryngologic Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Nose Diseases
- Hypersensitivity
- Asthma
- Rhinitis
- Rhinitis, Allergic
Other Study ID Numbers
- NI-MT-05
- ID-RCB:2017-A02668-45 (Other Identifier: Comité de Protection des Personnes SUD MEDITERRANNEE IV)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Rhinitis Due to House Dust Mite
-
ALK-Abelló A/SActive, not recruitingAllergic Rhinitis Due to Dermatophagoides Farinae | Allergic Rhinitis Due to Dermatophagoides Pteronyssinus | Allergic Rhinitis Due to House Dust MiteSpain, Russian Federation, United States, Poland, Bulgaria, Canada, France, Germany, Lithuania, Slovakia, Ukraine
-
ALK-Abelló A/SCompletedAllergic Rhinitis Due to House Dust Mite | Allergic Asthma Due to Dermatophagoides Farinae | Allergic Asthma Due to Dermatophagoides PteronyssinusPoland, United Kingdom, Spain, United States, Russian Federation, Hungary, France, Bulgaria, Germany
-
Eye & ENT Hospital of Fudan UniversityNot yet recruitingAllergic Rhinitis Due to House Dust Mite
-
Gadjah Mada UniversityEnrolling by invitationAllergic Rhinitis | Allergic Rhinitis Due to House Dust MiteIndonesia
-
ALK-Abelló A/SEnrolling by invitationAllergic Asthma | Allergic Rhinitis Due to House Dust MiteChina
-
Inmunotek S.L.LAT Research; Xolomon Tree S.L.Not yet recruitingAllergic Rhinitis | Allergic Asthma | Allergic Rhinoconjunctivitis | Allergy to House Dust MiteArgentina
-
Astellas Pharma Global Development, Inc.Active, not recruitingAllergic to House Dust MitesGermany
-
Inmunotek S.L.BioClever 2005 S.L.; NTS hub S.LTerminatedEfficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/RhinoconjunctivitisPerennial Allergic Rhinitis | Allergic Rhinoconjunctivitis | House Dust Mite Allergy | Pollen AllergySpain
-
Cytos Biotechnology AGCompletedPerennial Allergy to House Dust Mite and/or CatEstonia, Latvia, Lithuania
-
Stallergenes GreerTerminatedAllergic Rhinitis Due to Dust Mite
Clinical Trials on Tablet, Dispersible
-
University Hospital, Basel, SwitzerlandCompleted
-
Chulalongkorn UniversityRecruitingPediatric HIV InfectionThailand
-
BayerCompletedPharmacokineticsGermany
-
Novartis PharmaceuticalsCompletedChronic Iron Overload Due to Transfusion-dependant AnemiasItaly, Austria, Thailand, Spain, Germany, Mexico, Malaysia, Greece, United Kingdom, France, Saudi Arabia, United Arab Emirates, Lebanon, Russian Federation, United States, Argentina
-
SpringWorks Therapeutics, Inc.Active, not recruitingPlexiform Neurofibroma | Neurofibromatosis Type 1 (NF1)United States
-
International Centre for Diarrhoeal Disease Research...Completed
-
University of OxfordKenya Medical Research InstituteCompletedNutrition Disorders | Life-threatening InfectionKenya
-
Suzana Erico Tanni MinamotoLiita Care ApSCompleted
-
sigma-tau i.f.r. S.p.A.CompletedMalaria,FalciparumBurkina Faso, Congo, The Democratic Republic of the, Gambia, Mozambique, Tanzania
-
The First Affiliated Hospital with Nanjing Medical...Unknown